Lyell Immunopharma LYEL 深 沪
等待开盘 08-15 09:30:00 美东时间
10.76
-0.070
-0.65%
华盛通- 最 高10.7999
- 今 开10.52
- 成交量 2.31万股
- 最 低 10.1901
- 昨 收 10.83
- 总市值 1.59亿
- 52周最高 32.10
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 7.65
- 委 比 -98.02%
- 总股本 1480.81万
- 历史最高 396.80
- 量 比 0.52
- 振 幅 5.63%
- 历史最低 7.80
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lyell Immunopharma reports Q2 results
Lyell Immunopharma press release (NASDAQ:LYEL): Q2 net loss of $42.7 million Revenue of $8K, vs. $13K a year ago More on Lyell Immunopharma Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment ...
08-13 05:06
Lyell Immunopharma Q2 EPS $(2.89) Beats $(3.82) Estimate, Sales $8.000K Down From $13.000K YoY
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(2.89) per share which beat the analyst consensus estimate of $(3.82) by 24.4 percent. This is a 19.5 percent increase over losses of $(3.59) per share from
08-13 04:34
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Lyell Immunopharma shares are trading higher after the company announced a private placement worth up to $100 million.
Lyell Immunopharma shares are trading higher after the company announced a priv...
07-25 20:48
Lyell Immunopharma registers 625,000 shares for resale
Lyell Immunopharma (NASDAQ:LYEL) registers 625,000 common shares for resale by selling stockholders. Shares were issued as additional merger consideration under the October 2024 merger agreement with ...
07-19 04:42
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
HC Wainwright & Co. Maintains Neutral on Lyell Immunopharma, Raises Price Target to $10
HC Wainwright & Co. analyst Mitchell Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Neutral and raises the price target from $1 to $10.
06-24 19:01
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
Lyell Immunopharma announces that its senior management will participate in the H.C. Wainwright "HCW@Home" Series on June 25, 2025, to discuss new clinical data on LYL314, its lead CAR T-cell therapy for relapsed and/or refractory large B-cell lymphoma (LBCL). LYL314, which targets CD19/CD20, has received FDA RMAT and Fast Track designations and aims to improve response rates and durability compared to existing therapies. The webcast will provide...
06-23 21:00
Lyell Immunopharma Announced New Clinical Data From Phase 1/2 Trial Of LYL314, In Patients Treated In The 3L+ Setting (N = 25), LYL314 Showed An 88% Overall Response Rate And A 72% Complete Response Rate
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response
06-17 18:32
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
Lyell Immunopharma announced positive clinical data for LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy, in patients with relapsed/refractory large B-cell lymphoma (LBCL). In a Phase 1/2 trial of 25 patients treated in the third- or later-line setting, LYL314 demonstrated an 88% overall response rate and a 72% complete response rate. Of those achieving complete response, 71% remained in remission at ≥6 months. The therapy exhibited a manage...
06-17 10:30
